As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The ...

MOUNT PLEASANT, S.C. (WCIV) — The Alzheimer’s Association South Carolina Chapter is gearing up for its "Ride to End ALZ South Carolina" cycling event. The annual, three-day ride will be held from July ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from ...

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard ...

New Results Position ALZ-801 Tablet to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease ...

An experimental pill could slow memory loss and brain shrinkage in some Alzheimer’s patients, new research suggests. The pill, called ALZ-801 (valiltramiprosate), was shown to be effective in people ...

Please provide your email address to receive an email when new articles are posted on . Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer's disease, the ...

Allianz SE, together with its subsidiaries, provides property-casualty insurance, life/health insurance, and asset management products and services Internationally. The company’s Property-Casualty ...

Saturday, September 13th Mercy Park, 3002 St. John's Boulevard, Joplin Event opens at 8:30 Opening Ceremony at 10:00 Food, Kid Zone and Pet Area - so bring the family Held annually in more than 600 ...

Please provide your email address to receive an email when new articles are posted on . Earlier initiation of donanemab reduced the risk of disease progression on the Clinical Dementia Rating-Global ...